Minerva Neurosciences (NERV) Phase 3 Trial of Roluperidone for Treatment of Negative Symptoms in Schizophrenia Did Not Meet Its Primary and Key Secondary Endpoints

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/7/2026

1. SPCX
2. CRNX
3. VRTX
4. RIVN
5. LMT
6. WMT
7. RXST
8. SPGI
9. AGIO
10. NCNO

Go back to Minerva Neurosciences (NERV) Phase 3 Trial of Roluperidone for Treatment of Negative Symptoms in Schizophrenia Did Not Meet Its Primary and Key Secondary Endpoints

Minerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia

May 29, 2020 9:20 AM EDT

The 64 mg and 32 mg doses were not statistically significantly different from placebo at Week 12 on the primary endpoint, the PANSS Marder Negative Symptoms Factor Score (p 0.064 and 0.259, respectively), or the key secondary endpoint, the Personal and Social Performance Scale Total Score (p 0.021 and p 0.542, respectively)Roluperidone separated from placebo on both primary and key secondary endpoints at Weeks 4, 8 and 12Roluperidone was generally well tolerated with a safety profile comparable to placebo

WALTHAM, Mass., May 29, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a... More